跳至主要内容
临床试验/EUCTR2016-000494-20-SE
EUCTR2016-000494-20-SE进行中(未招募)1 期

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aromatase inhibitors alone or in combination with a cdk4/6 inhibitor) in Patients With Advanced Breast Cancer

Skåne University Hospital, Department of Oncology0 个研究点目标入组 126 人开始时间: 2016年5月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
126

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1.Patients diagnosed with ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic
  • endocrine based treatment. If IHC analysis is not available from the metastatic tissue, the ER and HER2 status is determined from archived
  • primary tumor.
  • 2.Age > 18 years.
  • 3.Performance status of Eastern Cooperative Oncology Group (ECOG) = 2.
  • 4.Metastatic disease must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination,
  • computerized tomography (CT), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET). Bone
  • metastases alone are allowed.
  • 5.Pre-menopausal patients must consent to undergo either surgical or chemical castration during the duration of the treatment and utilize an
  • effective contraception barrier method.
  • 6.Patient not willing to undergo study specific biopsy from the metastatic site should preferably have enough metastatic tumor sample
  • material archived to perform DNA extraction from formalin fixed paraffin embedded (FFPE) material.
  • 7.Patient must be capable and willing to grant signed informed consent prior to any procedure related with this study as well as to allow
  • access to FFPE biopsies for DNA extraction and for serial CTCs ctDNA analysis. Biopsy of the metastatic site upon progression is not
  • mandatory but desirable.
  • 8.Signed informed consent according to ICH/GCP, and national/local regulations.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 26

排除标准

  • 1.Previous treatment for metastatic breast cancer (previous systemic treatment for early breast cancer allowed).
  • 2.Brain as the only site of metastatic breast cancer.
  • 3.Ongoing treatment with statins (e.g. simvastatin, atorvastatin, fluvastatin, lovastatin, pravastatin, or rosuvastatin), anion-exchangers (e.g.
  • colestyramin or colesevelam), fibrates (e.g. gemfibrozil), nicotin-acids (or acipimox) or inhibitors of intestinal cholesterol uptake (e.g.
  • ezitimibe) for the first part of the trial.
  • 4.Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal
  • dysfunction (creatine kinase level) more than three times the upper limit of the normal range.
  • 5.The patient is unable to pause treatment with anticoagulants/antiagregants prior to biopsy during the recommended times.
  • 6.History of haemorrhagic stroke.
  • 7.Pregnancy or breast-feeding.
  • 8.Untreated psychiatric disorders that will impair the patient’s ability to comply with study treatment or protocol.
  • 9.History of allergic reactions attributed to compounds of similar chemical or biological composition to either of the study drugs.

研究者

发起方
Skåne University Hospital, Department of Oncology

相似试验